Biopartnering Seminar: A Discussion on Commercial Opportunity for CRISPR Technology

EMEND BioConsulting Photo
Tuesday, October 25, 2016 - 6:30pm

The clustered regularly interspaced short palindromic repeats (CRISPR) system is a revolutionary gene editing tool that is primed to be commercialized in the near future. The three major markets that will be evaluated are gene therapy, diagnostics and agriculture; we will seek to identify the most practical and near term market of these three. Firstly, the market for gene therapies is in its early stages, therefore Strimvelis will be used as a best in class example for evaluating CRISPR’s potential. Secondly, CRISPR shows promise in being a novel diagnostic method that delivers results quicker than the traditional methods currently utilized. The Zika virus epidemic has brought about an influx of diagnosis systems for the early detection of the disease. These systems are commercially sold after passing through the emergency use authorization process set by the FDA. Thirdly, DuPont Pioneer has plans to commercialize a waxy corn hybrid developed through CRISPR and bring it to the market in 5 years. Current waxy corn strains are limited by poor yields, however a new hybrid constructed with CRISPR technologies that has been shown to increase yield. The waxy corn market is the best near-term commercial opportunity for CRISPR because a hybrid strain can be brought quickly to the market due to the lack of regulatory hurdles that surround similar GMO crops. This hybrid has the potential to take over the waxy corn market because of its ability to yield more product than other strains.

Team: EMEND BioConsulting

Team Members: Mihnea Alb, Dimitri De Mel, Alina Kopteva, Abraham Kuot, Christine Paputsis, Shathveekan Sivanathan

Date: Tuesday, October 25th, 2016 at 6:30pm

Location: Instructional Centre, Room 120

Everyone Welcome! Light refreshments will be served at 6pm.